Citadel Advisors’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Citadel Advisors’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-70,701	Closed	-$926	–	15746
2024 Q3	$926	Buy	70,701 +200	+0.3%	+$6	﹤0.01%	13932
2024 Q2	$2.97K	Buy	70,501 +54,628	+344%	+$3.47K	﹤0.01%	13638
2024 Q1	$825	Buy	+15,873	New	+$952	﹤0.01%	14237

Other funds holding CLDI.WS

EAM

Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return

Citadel Advisors's CLDI.WS Position: Q4 2024 in Review

Citadel Advisors sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q4 2024, closing a stake of 70,701 shares — an estimated $926 sold.

Citadel Advisors first reported a position in CLDI.WS in Q1 2024 and held it in 3 quarters. The position peaked at $2.97K in Q2 2024. 1 fund tracked by Wall St. Rank holds CLDI.WS as of Q4 2024.

Citadel Advisors reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q4 2024 after selling out during the quarter.
Citadel Advisors sold 70,701 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q4 2024, an estimated $926.
Citadel Advisors first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q1 2024 and held it in 3 quarters.
Citadel Advisors's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $2.97K in Q2 2024.
1 fund tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.